13011998
Biomarkers of the Exhaled Breath and Single-Lead Electrocardiography in the Diagnosis of Myocardial Ischemia
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT06181799/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- В исследовании участвуют здоровые добровольцы.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 40 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 80 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (06.2024) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Биомаркеры в критерияхEGFR
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 22 · невключение: 4
Критерии включения
- Age ≥40 years;
- Absence of acute exacerbations of psychiatric disorders or cognitive impairments that would preclude study participation;
- Provision of written informed consent for study participation, blood sample collection, and anonymous publication of research results;
- Pre-test probability of ischemic heart disease between 1% and 33%.
- Non-inclusion criteria:
- Pregnancy and breastfeeding;
- Diabetes mellitus;
- Presence of acute myocardial ischemia (acute coronary syndrome or myocardial infarction within the preceding 48 hours) or a history of myocardial infarction;
- Active infectious or non-infectious inflammatory diseases in the acute/exacerbation phase;
- Connective tissue diseases (regardless of disease activity);
- Respiratory disorders (e.g., bronchial asthma, chronic bronchitis, cystic fibrosis, or other conditions associated with significant respiratory dysfunction);
- Acute pulmonary thromboembolism involving the pulmonary artery or its branches;
- Aortic dissection;
- Hemodynamically significant decompensated cardiac valvular defects**;
- Active malignancy;
- Decompensated chronic heart failure (NYHA class III-IV) or acute heart failure;
- Neurological disorders (e.g., Parkinson's disease, multiple sclerosis, acute psychosis, Guillain-Barré syndrome);
- Cardiac arrhythmias or conduction abnormalities contraindicating stress testing;
- Musculoskeletal disorders precluding exercise testing (e.g., bicycle ergometry);
- Allergy to radiocontrast agents and/or adenosine triphosphate (ATP);
- Chronic kidney disease with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m² (CKD-EPI formula);
- Severe hepatic insufficiency and/or Child-Pugh class B or C liver cirrhosis.
Критерии невключения
- Poor recording quality of single-channel electrocardiogram (ECG) and/or plethysmography data;
- Failure to complete the stress test due to reasons unrelated to cardiac conditions;
- Voluntary withdrawal of consent to continue participation in the study;
- Post-enrollment development of conditions or identification of pathologies listed in the exclusion criteria.
Источник: ClinicalTrials.gov, NCT06181799 · запись обновлена в реестре 15 августа 2025.
Дизайн и результаты
Что измеряют — первичные конечные точки (7)
- Diagnostic Accuracy (AUC, Sensitivity, Specificity, NPV, PPV) of the Stress-ECG Test in Ischemic Heart Disease — The study was completed on 10.06.2024; the outcome measure was assessed during 6 months for the stress electrocardiography test
- Diagnostic Accuracy (AUC, Sensitivity, Specificity, NPV, PPV) of Exhaled Breath Analysis for Ischemic Heart Disease — The study was completed on 10.06.2024; the outcome measure was assessed during 6 months for the obtained volatilome data.
- Diagnostic Accuracy (AUC, Sensitivity, Specificity, NPV, PPV) of Single-Lead ECG With Pulse Wave Analysis in Ischemic Heart Disease — The study was completed on 10.06.2024; the outcome measure was assessed during 6 months for the single lead ECG parameters with pulse wave function
- Changes in the Concentration of Total Cholesterol, TG (mmol/L), LDL (mmol/L), LDL (mmol/L), HDL (mmol/L), and VLDL (mmol/L) in Individuals With Stress-induced Myocardial Perfusion Defect vs. Without. — The study was completed on 10.06.2024; the outcome measure was assessed during 1 week for the total cholesterol, TG (mmol/L), LDL (mmol/L), LDL (mmol/L), HDL (mmol/L), and VLDL (mmol/L) data.
- Changes in the Concentration of Apolipoprotein B (g/L) in Individuals With Stress-induced Myocardial Perfusion Defect vs. Without. — The study was completed on 10.06.2024; the outcome measure was assessed during 1 week for the Apolipoprotein В (g/L) data.
- Changes in the Concentration of Lipoprotein (а) (mg/L) and c-RP (mg/L) in Individuals With Stress-induced Myocardial Perfusion Defect vs. Without. — The study was completed on 10.06.2024; the outcome measure was assessed during 1 week for the lipoprotein (а) (mg/L) and c-RP (mg/L) data.
- Changes in the Concentration of IL- 6 (pg/mL) in Individuals With Stress-induced Myocardial Perfusion Defect vs. Without. — The study was completed on 10.06.2024; the outcome measure was assessed during 1 week for the IL- 6 (pg/mL) data.
Цель исследования
This is a prospective, case-control, single-center, observational, non-randomized study. It is designed to evaluate the diagnostic accuracy of functional tests involving physical exertion monitored via a 12-lead ECG, combined with analysis of exhaled breath volatile organic compounds (VOCs) and single-lead ECG parameters.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT06181799 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.